Literature DB >> 27426939

Case-control study evaluating competing risk factors for angioedema in a high-risk population.

Rebecca J Kamil1, Elina Jerschow2, Patricia A Loftus1, Melin Tan1, Marvin P Fried3, Richard V Smith1, David Foster, Thomas J Ow1,4.   

Abstract

OBJECTIVES/HYPOTHESIS: Black race is a risk factor for angioedema. The primary aim was to examine the relationship between race-ethnicity and risk factors for angioedema. STUDY
DESIGN: Using a retrospective case-control study design, data was extracted with the Clinical Looking Glass utility, a data collection and management tool that captures data from electronic medical record systems within the Montefiore Healthcare System. Cases were emergency department (ED) visits with primary or secondary International Classification of Diseases, Ninth Revision, code diagnoses of angioedema in adults aged ≥ 18 years from January 2008 to December 2013 at three Montefiore centers in Bronx, New York. Controls were a random sampling of adult ED visits during the same period.
METHODS: In primary analyses, angiotensin-converting enzyme inhibitor (ACE-I) and black race were evaluated for synergy. The influence of different risk factors in the development of angioedema was evaluated using logistic regression models. Finally, race-ethnicity was further explored by evaluating for effect modification by stratification of models by race-ethnicity categories.
RESULTS: There were 1,247 cases and 6,500 controls randomly selected from a larger control pool. ACE-I use (odds ratio [OR] 3.70, 95% confidence interval [CI] 2.98, 4.60), hypertension (OR 1.88, 95% CI 1.55, 2.29), and black race (OR 2.25, 95% CI 1.86, 2.72) were the strongest risk factors. ACE-I use and black race were not synergistic (OR 1.10, 95% CI 0.80, 1.51). Race-ethnicity was an effect modifier for certain risk factors.
CONCLUSION: Race-ethnicity acts as an effect modifier for particular angioedema risk factors. The two strongest risk factors, ACE-I use and black race, were not synergistic. LEVEL OF EVIDENCE: 3b. Laryngoscope, 126:1823-1830, 2016.
© 2016 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Angioedema; race; risk factors

Mesh:

Substances:

Year:  2016        PMID: 27426939      PMCID: PMC4955864          DOI: 10.1002/lary.25821

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  30 in total

Review 1.  Hereditary angioedema with normal C1 inhibitor.

Authors:  Konrad Bork
Journal:  Immunol Allergy Clin North Am       Date:  2013-09-05       Impact factor: 3.479

2.  Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.

Authors:  Alencia V Woodard-Grice; Amelia C Lucisano; James B Byrd; Elizabeth R Stone; William H Simmons; Nancy J Brown
Journal:  Pharmacogenet Genomics       Date:  2010-09       Impact factor: 2.089

3.  Incidence and characteristics of angioedema associated with enalapril.

Authors:  John B Kostis; Harold J Kim; James Rusnak; Thomas Casale; Allen Kaplan; Jonathan Corren; Elliott Levy
Journal:  Arch Intern Med       Date:  2005-07-25

Review 4.  The plasma bradykinin-forming pathways and its interrelationships with complement.

Authors:  Allen P Kaplan; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

5.  Autoimmune diseases: a leading cause of death among young and middle-aged women in the United States.

Authors:  S J Walsh; L M Rau
Journal:  Am J Public Health       Date:  2000-09       Impact factor: 9.308

Review 6.  Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.

Authors:  Z H Israili; W D Hall
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

7.  Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007.

Authors:  Marya D Zilberberg; Brian H Nathanson; Thomas Jacobsen; Glenn Tillotson
Journal:  Allergy Asthma Proc       Date:  2011-05-04       Impact factor: 2.587

8.  Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.

Authors:  N J Brown; W A Ray; M Snowden; M R Griffin
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

9.  Increasing hospitalizations due to angioedema in the United States.

Authors:  Robert Y Lin; Shaili N Shah
Journal:  Ann Allergy Asthma Immunol       Date:  2008-08       Impact factor: 6.347

Review 10.  Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?

Authors:  Domenic A Sica; Henry R Black
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Sep-Oct       Impact factor: 3.738

View more
  2 in total

1.  Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study.

Authors:  Robert J Fontana; Sabela Lens; Stuart McPherson; Magdy Elkhashab; Victor Ankoma-Sey; Mark Bondin; Ana Gabriela Pires Dos Santos; Zhenyi Xue; Roger Trinh; Ariel Porcalla; Stefan Zeuzem
Journal:  Adv Ther       Date:  2019-10-23       Impact factor: 3.845

2.  Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.

Authors:  Jone Jackeviciute; Vidas Pilvinis; Rugile Pilviniene
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.